- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01445171
Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- AKH Vienna-Allgemeines Krankenhaus der Stadt Wien; University Vienna
-
-
-
-
-
Bad Nauheim, Germany, 61231
- Kerchoff Klinik-Bad Nauheim
-
Hannover, Germany, 30625
- MHH-Medizinische Hoschschule Hannover
-
Koeln, Germany, 50937
- Herzzentrum Uniklink Koln-Klinik und Poliklinik fur Herz und Thoraxzchirurgie
-
Leipzig, Germany, 04289
- University Leipzig: Herzzentrum Leipzig Gmbh
-
Munich, Germany, 81377
- Klinikum der Universitat Muchen-Grosshadern; Clinic at the University of Munich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Criteria:
Inclusion Criteria:
- 18 years or older
- Aortic stenosis or stenosis-insufficiency of aortic valve requiring a planned replacement as indicated in the preoperative evaluation;
- Scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, MAZE procedure, septal myectomy, pacemaker/ICD implant and or atrial appendage occlusion/removal.
- Signed and dated the informed consent form prior to investigation procedures;
- Geographically stable and agrees to attend Follow up assessments at the hospital of surgical services for a maximum of 5 years.
Exclusion Criteria:
- Pure aortic insufficiency
- Requires emergency surgery
- Aneurysm of the aortic root and/or ascending aorta requiring surgical intervention
- Left ventricular ejection fraction of ≤ 25%
- Active endocarditis within 3 months prior to the scheduled aortic valve replacement surgery
- Concomitant valve (mitral, tricuspid, or pulmonic) disease requiring repair with an annuloplasty ring or replacement with prosthesis
- Prior mitral, tricuspid or pulmonic valve surgery, which included implantation of a bioprosthetic valve, mechanical valve, or annuloplasty ring.
- Myocardial infarction (MI) within 1 month prior to the scheduled aortic valve replacement surgery
- Previously implanted with EDWARDS INTUITY Aortic valve; alcohol or drug abuser
- Disease limiting life expectancy to less than 12 months
- Pregnant or lactating
- Currently participating in another drug or device clinical investigation;
- Documented blood diatheses
- Requires non-cardiac procedures such as carotid procedures or mediastinal tumor removal
- Had a stroke or transient ischemic attack (TIA) within 6-months prior to scheduled aortic valve replacement surgery
- Study site pre-operative echocardiographic assessment shows evidence of an intracardiac mass, thrombus, or vegetation
- Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days of procedure
- Documented renal insufficiency as determined by Serum creatinine ≥ 200 µmol/L (2.27 mg/dL) at screening or end-stage renal disease requiring chronic dialysis
- Documented hyperparathyroidism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Study Valve
Subjects act as own control
|
Aortic Valve bioprosthesis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Early Adverse Events
Time Frame: Events occuring within 30 days of procedure
|
Number of early adverse events occurring within 30 days of procedure divided by the total number of enrolled subjects times 100.
|
Events occuring within 30 days of procedure
|
Percent of Late Adverse Events
Time Frame: Events occurring >= 31 days and up through 5 years post-implant
|
Number of late adverse events divided by the total number of late patient years times 100.
Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).
|
Events occurring >= 31 days and up through 5 years post-implant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subject's With Device Technical Success
Time Frame: At time of surgery, an average of 3 hours
|
Device technical success is defined as the successful delivery and deployment of one bioprosthesis with one delivery system with a maximum of two attempts.
|
At time of surgery, an average of 3 hours
|
Number of Subject's With Procedural Success
Time Frame: Discharge(an average of 13 days) or 10 days post-implant, whichever comes first
|
Procedure success is defined as device technical success followed by the absence of adverse events requiring device reoperation, requiring implantation of permanent pacemaker, or subject death.
|
Discharge(an average of 13 days) or 10 days post-implant, whichever comes first
|
Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline
Time Frame: 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases. |
1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
Subject's Average Score on the EQ-5D- Quality of Life Questionnaire Over Time
Time Frame: Baseline, 3 Months, and 1 Year post-implant
|
The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000.
A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.
|
Baseline, 3 Months, and 1 Year post-implant
|
Subject's Average Mean Systolic Gradient Measurements Over Time.
Time Frame: Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Gradients are evaluated by echocardiography over time.
Mean gradient values depend on the size and type of valve.
|
Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
Subject's Average Effective Orifice Area Measurements Over Time.
Time Frame: Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve.
Effective orifice area is evaluated by echocardiography over time.
|
Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
Subject's Amount of Aortic Valvular Regurgitation Over Time
Time Frame: Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it.
Aortic valvular regurgitation is evaluated by echocardiography over time.
It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.
|
Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant
|
Subject's Average White Blood Cell Count Measurement Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Laboratory analysis of White Blood Cell Count on blood drawn from subject; WBC fight infection.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Subject's Average Red Blood Cells Count Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Laboratory Analysis of Red Blood Cell Count on blood drawn from subjects; RBC carry oxygen.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Subject's Average Hemoglobin Count Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Laboratory Analysis of Hemoglobin Count on blood drawn from subjects.
Hemoglobin is an oxygen-carrying protein in red blood cells.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Subject's Average Hematocrit Percentage Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects.
Hematocrit is the proportion of red blood cells to the fluid component (plasma) in the blood.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Subject's Average Platelet Count Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Subject's Average Reticulocytes Percentage Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Reticulocytes are immature red blood cells; a reticulocyte blood test measures the amount of these cells in the blood.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Subject's Average Haptoglobin Measurement Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Laboratory Analysis of Haptoglobin on blood drawn from subjects; Haptoglobin is a protein produced by the liver.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Subject's Average Serum LDH Measurement Over Time.
Time Frame: Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
The lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues.
|
Baseline, 3 Months, 1 Year, and 5 Years post-implant
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Prof Axel Haverich, MHH Hannover
Publications and helpful links
General Publications
- Laufer G, Haverich A, Andreas M, Mohr FW, Walther T, Shrestha M, Rahmanian P, Holzhey D, Roth M, Schmitz C, Schramm R, Giot C, Wahlers TCW. Long-term outcomes of a rapid deployment aortic valve: data up to 5 years. Eur J Cardiothorac Surg. 2017 Aug 1;52(2):281-287. doi: 10.1093/ejcts/ezx103.
- Haverich A, Wahlers TC, Borger MA, Shrestha M, Kocher AA, Walther T, Roth M, Misfeld M, Mohr FW, Kempfert J, Dohmen PM, Schmitz C, Rahmanian P, Wiedemann D, Duhay FG, Laufer G. Three-year hemodynamic performance, left ventricular mass regression, and prosthetic-patient mismatch after rapid deployment aortic valve replacement in 287 patients. J Thorac Cardiovasc Surg. 2014 Dec;148(6):2854-60. doi: 10.1016/j.jtcvs.2014.07.049. Epub 2014 Aug 1.
- Kocher AA, Laufer G, Haverich A, Shrestha M, Walther T, Misfeld M, Kempfert J, Gillam L, Schmitz C, Wahlers TC, Wippermann J, Mohr FW, Roth M, Skwara A, Rahmanian P, Wiedemann D, Borger MA. One-year outcomes of the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON) trial: a prospective multicenter study of rapid-deployment aortic valve replacement with the EDWARDS INTUITY Valve System. J Thorac Cardiovasc Surg. 2013 Jan;145(1):110-5; discussion 115-6. doi: 10.1016/j.jtcvs.2012.07.108. Epub 2012 Oct 8.
- Wahlers TCW, Andreas M, Rahmanian P, Candolfi P, Zemanova B, Giot C, Ferrari E, Laufer G. Outcomes of a Rapid Deployment Aortic Valve Versus Its Conventional Counterpart: A Propensity-Matched Analysis. Innovations (Phila). 2018 May/Jun;13(3):177-183. doi: 10.1097/IMI.0000000000000509.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
BC Centre for Improved Cardiovascular HealthEdwards LifesciencesUnknownTranscatheter Aortic Valve Implantation | Severe Aortic StenosisCanada
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Hospices Civils de LyonRecruiting
Clinical Trials on Aortic Valve Replacement with EDWARDS INTUITY Valve System
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Valve DiseaseGermany
-
Edwards LifesciencesCompleted
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaMinistry of Health, Italy; Region Emilia-Romagna, ItalyCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedSevere Aortic Valve DiseaseFrance
-
UMC UtrechtTerminatedPeriprosthetic Aortic Valve Regurgitation After TAVINetherlands
-
Edwards LifesciencesActive, not recruitingMitral Valve Regurgitation (Degenerative or Functional)United States, Canada
-
Corcym S.r.lCompleted
-
Edwards LifesciencesActive, not recruitingCardiovascular Diseases | Heart Valve Diseases | Tricuspid Valve RegurgitationUnited States, Canada, France, Switzerland
-
Edwards LifesciencesCompletedCritical Aortic StenosisUnited States, Canada, Germany